Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$1.91 -16.6%	$1.95	$1.33 ▼ $3.58	$89.98M	0.74	63,526 shs	151,106 shs
CAPR Capricor Therapeutics	$8.04 +2.8%	$9.55	$3.79 ▼ $23.40	$367.27M	0.59	2.04 million shs	2.02 million shs
HUMA Humacyte	$1.80 +2.9%	$2.38	$1.15 ▼ $7.48	$278.44M	1.9	3.96 million shs	6.98 million shs
KOD Kodiak Sciences	$8.52 +6.1%	$5.14	$1.92 ▼ $11.60	$449.52M	2.41	421,212 shs	463,978 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	+5.53%	+17.50%	+19.90%	+33.14%	+2.69%
CAPR Capricor Therapeutics	-13.78%	+1.82%	+2.36%	+7.12%	+107.98%
HUMA Humacyte	-29.44%	-22.57%	-24.24%	+1.16%	-77.88%
KOD Kodiak Sciences	+1.65%	+9.85%	+77.26%	+99.26%	+229.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	2.9829 of 5 stars	3.5	5.0	0.0	2.6	1.7	0.0
CAPR Capricor Therapeutics	3.6254 of 5 stars	4.6	4.0	0.0	2.8	0.8	0.6
HUMA Humacyte	1.676 of 5 stars	3.5	1.0	0.0	1.6	0.8	0.6
KOD Kodiak Sciences	2.6098 of 5 stars	1.0	1.0	4.6	3.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	3.00	Buy	$7.50	292.67% Upside
CAPR Capricor Therapeutics	3.11	Buy	$22.56	180.54% Upside
HUMA Humacyte	3.00	Buy	$10.64	492.92% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	5.63% Upside

Current Analyst Ratings Breakdown

Latest ADAG, CAPR, HUMA, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	HUMA Humacyte	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.50
8/12/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
8/11/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/6/2025	ADAG Adagene	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	ADAG Adagene	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/23/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/14/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/14/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $12.00
7/11/2025	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00
7/11/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$77.00 ➝ $24.00
7/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$100K	899.80	N/A	N/A	$1.14 per share	1.68
CAPR Capricor Therapeutics	$22.27M	16.49	N/A	N/A	$3.20 per share	2.51
HUMA Humacyte	$1.57M	177.35	N/A	N/A	($0.41) per share	-4.38
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	-$40.47M	-$1.42	N/A	N/A	N/A	-181.71%	-62.42%	-48.36%	8/13/2025 (Estimated)
HUMA Humacyte	-$148.70M	-$0.69	N/A	N/A	N/A	N/A	N/A	-73.59%	N/A
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)

Latest ADAG, CAPR, HUMA, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	CAPR Capricor Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$2.60 million	N/A
8/11/2025	Q2 2025	HUMA Humacyte	-$0.15	-$0.24	-$0.09	-$0.24	$0.94 million	$0.30 million
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/13/2025	Q1 2025	CAPR Capricor Therapeutics	-$0.33	-$0.53	-$0.20	-$0.53	$3.16 million	$2.73 million
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.30	2.30
CAPR Capricor Therapeutics	N/A	6.55	6.55
HUMA Humacyte	0.36	3.68	3.28
KOD Kodiak Sciences	N/A	4.62	4.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
CAPR Capricor Therapeutics	21.68%
HUMA Humacyte	44.71%
KOD Kodiak Sciences	89.06%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
CAPR Capricor Therapeutics	10.50%
HUMA Humacyte	5.10%
KOD Kodiak Sciences	45.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
CAPR Capricor Therapeutics	101	45.68 million	40.88 million	Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable

ADAG, CAPR, HUMA, and KOD Headlines

Recent News About These Companies

Federated Hermes Inc. Acquires Shares of 84,006 Kodiak Sciences Inc. (NASDAQ:KOD)

August 11 at 4:41 AM | marketbeat.com

Kodiak Sciences (KOD) to Release Quarterly Earnings on Wednesday

August 11 at 3:13 AM | americanbankingnews.com

Kodiak Sciences (KOD) to Release Earnings on Wednesday

August 6, 2025 | marketbeat.com

Kodiak Sciences Inc. (NASDAQ:KOD) Shares Bought by GSA Capital Partners LLP

August 4, 2025 | marketbeat.com

Kodiak Sciences Inc. (KOD) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Tsunami alerts for Alaska canceled after 7.3-magnitude earthquake off Aleutians

July 18, 2025 | msn.com

Part 1: Johnson recounts PTSD treatment after May breakdown

July 17, 2025 | kodiakdailymirror.comK

Enduring the heat of California

July 15, 2025 | kodiakdailymirror.comK

Penny Stocks To Watch In July 2025

July 11, 2025 | finance.yahoo.com

NASDAQ:KOD Financials | Kodiak Sciences Inc - Investing.com

July 10, 2025 | investing.com

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

July 10, 2025 | prnewswire.com

Kodiak Sciences Inc. Advanced Charts | KOD | Barron's

July 9, 2025 | barrons.com

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society - Morningstar

June 27, 2025 | morningstar.comM

Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)

June 27, 2025 | ophthalmologytimes.comO

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

June 25, 2025 | prnewswire.com

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

June 13, 2025 | zacks.com

Trump’s cuts to fisheries science have industry and conservation groups sounding alarm

June 11, 2025 | kucb.orgK

Alaska Aerospace, UAF to partner on new space ventures

June 11, 2025 | kodiakdailymirror.comK

Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

June 5, 2025 | theglobeandmail.com

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025 | prnewswire.com

Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads

May 29, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, CAPR, HUMA, and KOD Company Descriptions

Adagene NASDAQ:ADAG

$1.91 -0.38 (-16.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.97 +0.06 (+3.09%)

As of 05:37 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Capricor Therapeutics NASDAQ:CAPR

$8.04 +0.22 (+2.81%)

Closing price 04:00 PM Eastern

Extended Trading

$8.01 -0.03 (-0.44%)

As of 05:34 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Humacyte NASDAQ:HUMA

$1.80 +0.05 (+2.87%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 +0.01 (+0.28%)

As of 05:38 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Kodiak Sciences NASDAQ:KOD

$8.52 +0.49 (+6.10%)

Closing price 04:00 PM Eastern

Extended Trading

$8.43 -0.09 (-1.10%)

As of 05:17 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time